D.A. Davidson & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

D.A. Davidson & Co’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-4,300	Closed	-$230K	–	1156
2017 Q4	$230K	Hold	4,300	–	–	﹤0.01%	958
2017 Q3	$256K	Sell	4,300 -50	-1%	-$3.02K	0.01%	914
2017 Q2	$343K	Buy	4,350 +100	+2%	+$8.18K	0.01%	735
2017 Q1	$352K	Sell	4,250 -700	-14%	-$52K	0.01%	724
2016 Q4	$392K	Hold	4,950	–	–	0.01%	734
2016 Q3	$346K	Hold	4,950	–	–	0.01%	755
2016 Q2	$192K	Buy	4,950 +150	+3%	+$6.25K	0.01%	859
2016 Q1	$194K	Hold	4,800	–	–	0.01%	855
2015 Q4	$425K	Buy	+4,800	New	+$379K	0.01%	590

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

D.A. Davidson & Co's EGRX Position: Q1 2018 in Review

D.A. Davidson & Co sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2018, closing a stake of 4,300 shares — an estimated $230K sold.

D.A. Davidson & Co first reported a position in EGRX in Q4 2015 and held it in 9 quarters. The position peaked at $425K in Q4 2015. 174 funds tracked by Wall St. Rank hold EGRX as of Q1 2018.

D.A. Davidson & Co reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
D.A. Davidson & Co sold 4,300 Eagle Pharmaceuticals, Inc. shares in Q1 2018, an estimated $230K.
D.A. Davidson & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 9 quarters.
D.A. Davidson & Co's Eagle Pharmaceuticals, Inc. position peaked at $425K in Q4 2015.
174 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2018.

Based on D.A. Davidson & Co's 13F filing for Q1 2018, filed 4 May 2018.